2022

• Osilodrostat (Isturisa®). HTA ID: 22023
• Ciltacabtagene autoleucel (Carvykti®). HTA ID: 22021
• Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®) for 1L RCC. HTA ID: 22018
• Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) HTA ID: 22022.
• Abemaciclib (Verzenios®) for adjuvant HR positive, HER2 negative, node positive early breast cancer. HTA ID: 22020
• Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone. HTA ID: 22016
• Defatted powder of Arachis hypogaea L., semen (peanuts) (Palforzia®). HTA ID: 22019
• Empagliflozin (Jardiance®). HTA ID: 21030
• Tixagevimab /cilgavimab (Evusheld®). HTA ID: 22015
• Solriamfetol (Sunosi®). HTA ID: 22017
• Risdiplam (Evrysdi™). HTA ID: 21006
• Caplacizumab (Cablivi®). HTA ID: 22013
• Somatrogon (Ngenla®). HTA ID: 22010
• Inclisiran (Leqvio®). HTA ID: 20051
• Finerenone (Kerendia®). HTA ID: 22012
• Trifluridine/tipiracil (Lonsurf®) for metastatic gastric cancer. HTA ID: 22011
• Nirmatrelvir/Ritonavir (Paxlovid®). HTA ID: 22014
• Avacopan (Tavneos®). HTA ID: 22009
• Sacituzumab govitecan (Trodelvy®). HTA ID: 22007
• Tofacitinib (Xeljanz®) for ankylosing spondylitis. HTA ID: 22005
• Pembrolizumab (Keytruda®) in combination with lenvatinib (Lenvima®) for endometrial carcinoma. HTA ID: 22006
• Apalutamide (Erleada®). HTA ID: 20010
• Levodopa/carbidopa/entacapone intestinal gel (Lecigon®). HTA ID: 21068
• Cefiderocol (Fetcroja®). HTA ID: 22003
• Tafasitamab (Minjuvi®) in combination with lenalidomide. HTA ID: 22008
• Inotersen (Tegsedi®). HTA ID: 19034
• Dupilumab (Dupixent®) for severe asthma. HTA ID: 21063
• Relugolix with estradiol and norethisterone acetate (Ryeqo®). HTA ID: 21055
• Amivantamab (Rybrevant®). HTA ID: 22004
• Venetoclax (Venclyxto®) for Acute Myeloid Leukaemia. HTA ID: 22001
• Ozanimod (Zeposia®) for Ulcerative Colitis. HTA ID: 22002
• Casirivimab/imdevimab (Ronapreve®). HTA ID: 21067
• Encorafenib (Braftovi®) in combination with cetuximab. HTA ID: 20037
• Pegcetacoplan (Aspaveli®). HTA ID: 21064
• Sotorasib (Lumykras™). HTA ID: 21070
• Oritavancin (Tenkasi®). HTA ID: 21061
• Fedratinib (Inrebic®). HTA ID: 21069
• Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066
• Lorlatinib (Lorviqua®) for 1L ALK positive NSCLC. HTA ID: 21071
• Pembrolizumab (Keytruda®) for metastatic triple negative breast cancer. HTA ID: 21059
• Cholic acid (Orphacol®). HTA ID: 21062
• Regdanvimab (RegkironaTM). HTA ID: 21065
• Bimekizumab (Bimzelx®). HTA ID: 21052

2021

• Molnupiravir (Lagevrio®). HTA ID: 21060
• Abrocitinib (Cibinqo®) HTA ID: 21056
• Mometasone furoate plus olopatadine (Ryaltris®). HTA ID: 21051
• Avelumab (Bavencio®) 1L maintenance urothelial carcinoma. HTA ID: 21001
• Odevixibat (Bylvay®). HTA ID: 21058
• Alpelisib (Piqray®) HTA ID: 20035
• Diroximel fumarate (Vumerity®). HTA ID 21047
• Baricitinib (Olumiant®) for atopic dermatitis. HTA ID: 21050
• Ketoconazole (Ketoconazole HRA®). HTA ID: 21046
• Filgotinib (Jyseleca®) HTA ID:21048
• Latanoprost/Timolol (Fixapost®) HTA ID: 21053
• Tirbanibulin (Klisyri®). HTA ID: 21054
• Dostarlimab (Jemperli®). HTA ID: 21045
• Nivolumab (Opdivo®) for advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma (1L). HTA ID: 21049.
• Tildrakizumab (Ilumetri®). HTA ID: 19029
• Larotrectinib (Vitrakvi ®) HTA ID: 19050
• Zanubrutinib (Brukinsa®). HTA ID: 21044
• Daratumumab (Darzalex®) HTA ID: 20025
• Bempedoic acid/Ezetimibe (Nustendi®) HTA ID: 20026b
• Bempedoic acid (Nilemdo®) HTA ID: 20026a
• Pegylated liposomal irinotecan (Onivyde®) HTA ID: 20028
• Hydrocortisone modified-release hard capsules (Efmody®). HTA ID: 21042
• Brentuximab vedotin (Adcetris®) for CD30+ Hodgkins lymphoma HTA ID: 19058
• Nivolumab (Opdivo®) for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer. HTA ID: 21043
• Upadacitinib (Rinvoq®) for psoriatic arthritis. HTA ID: 21040
• Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone. HTA ID: 21041
• Upadacitinib (Rinvoq®) for ankylosing spondylitis. HTA ID: 21039
• Ponesimod (Ponvory®). HTA ID: 21036
• Roxadustat (Evrenzo™). HTA ID: 21037
• Entrectinib (Rozlytrek®) for ROS1-positive advanced NSCLC. HTA ID: 21038
• Dupilumab (Dupixent®) for severe atopic dermatitis in children 6 to 11 years old. HTA ID: 21035
• Darolutamide (Nubeqa®). HTA ID: 20022
• Durvalumab (Imfinzi®) for 1L extensive-stage small cell lung cancer. HTA ID 21033
• Tofacitinib (Xeljanz®) for active polyarticular juvenile idiopathic arthritis. HTA ID: 21034
• Venetoclax (Venclyxto®) in combination with obinutuzumab (Gazyvaro®). HTA ID: 20046
• Risankizumab (Skyrizi®) HTA ID: 19010
• Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma . HTA ID: 21032
• Blinatumomab (Blincyto®). HTA ID: 21031
• Upadacitinib (Rinvoq®) for atopic dermatitis. HTA ID: 21029
• Tralokinumab (Adtralza®). HTA ID: 21028
• Ruxolitinib (Jakavi®) for Polycythaemia Vera. HTA ID: 20008
• Cabotegravir (Vocabria®) in combination with rilpivirine (Rekambys®). HTA ID: 21026
• Vericiguat (Verquvo®). HTA ID: 21027
• Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)
• Cannabidiol (Epidyolex®) for the treatment of Tuberous Sclerosis Complex. HTA ID: 21024
• Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 21020b
• Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 21020a
• Enzalutamide (Xtandi®) for mHSPC. HTA ID: 21022
• Cenobamate (Ontozry®). HTA ID: 21025
• Selparcatinib (Retsevmo®) for NSCLC. HTA ID: 21021
• Nintedanib (Ofev®) HTA ID: 20034
• Avelumab (Bavencio®) in combination with axitinib (Inlyta®) for first line treatment of metastatic renal cell carcinoma. HTA ID: 19046
• Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) (Colorectal cancer). HTA ID: 21023
• Olaparib (Lynparza®) for mCRPC. HTA ID: 21019
• Conestat alfa (Ruconest®). HTA ID: 21017
• Romosozumab (Evenity®). HTA ID: 21016
• Pembrolizumab (Keytruda®) for head and neck squamous cell carcinoma. HTA ID: 19051
• Pembrolizumab (Keytruda®) for classical Hodgkin Lymphoma. HTA ID: 21013
• Nivolumab in combination with ipilimumab (Opdivo® and Yervoy®) (malignant pleural mesothelioma). HTA ID: 21018
• Neratinib (Nerlynx®) HTA ID: 19057
• Onasemnogene abeparvovec (Zolgensma®). HTA ID: 20021
• Nivolumab plus Ipilimumab plus platinum-doublet chemotherapy (Opdivo® plus Yervoy®) (1L NSCLC). HTA ID: 21014
• Formoterol fumarate dihydrate, glycopyrronium, budesonide (Trixeo Aerosphere®). HTA ID: 21015
• Olaparib (Lynparza®) in combination with bevacizumab (1L maintenance HRD positive ovarian cancer). HTA ID: 21011
• Brentuximab vedotin (Adcetris®). HTA ID: 21010
• Atezolizumab (Tecentriq®) for 1L NSCLC. HTA ID: 21012
• Ofatumumab (Kesimpta®). HTA ID: 21008
• OTL-200 Autologous CD34+ cells encoding arylsulfatase A (ARSA) gene (Libmeldy®). HTA ID: 21009
• Niraparib (Zejula®); 1L maintenance OVCA. HTA ID: 21004
• Cemiplimab (Libtayo®). HTA ID: 21007
• Autologous anti-CD19-transduced CD3+ cells (Tecartus®). HTA ID: 21005
• Trastuzumab emtansine (Kadcyla®) HTA ID: 20002
• Esketamine (Spravato®) HTA ID: 19055
• Cannabidiol (Epidyolex®) for the treatment of Lennox-Gastaut Syndrome. HTA ID: 20005
• Cannabidiol (Epidyolex®) for the treatment of Dravet Syndrome. HTA ID: 20004
• Ceftazidime/avibactam (Zavicefta®). HTA ID: 21003
• Gilteritinib (Xospata®) for Relapsed or Refractory AML. HTA ID: 19043
• Pembrolizumab (Keytruda®) for colorectal cancer. HTA ID: 21002
• Siponimod (Mayzent®) HTA ID: 19053
• IUB™ Ballerine® MIDI 15mm diameter SCU300B. HTA ID: 20062
• Guselkumab (Tremfya®) for psoriatic arthritis. HTA ID 20059
• Semaglutide (Rybelsus®) HTA ID: 20011
• Polatuzumab vedotin (Polivy®) HTA ID: 19052
• Avatrombopag (Doptelet®). HTA ID: 20058
• Omeprazole (Pedippi®) 2mg/ml powder for oral suspension (HTA ID: 20049)
• Liraglutide (Saxenda®) HTA ID: 19039
• Atezolizumab (Tecentriq®) in combination with bevacizumab. HTA ID: 20060
• Acalabrutinib (Calquence®) HTA ID: 20063
• Baricitinib (Olumiant®) for moderate to severe atopic dermatitis. HTA ID: 20056
• Opicapone (Ongentys®). HTA ID: 20055
• Mogamulizumab (Poteligeo®). HTA ID: 20061
• Carfilzomib (Kyprolis®) in combination with daratumumab and dexamethasone (CAR+DAR+DEX). HTA ID: 20054
• Nivolumab (Opdivo®) as monotherapy for unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (2L). HTA ID: 20057
• Galcanezumab (Emgality®). HTA ID 20052
• Pertuzumab and trastuzumab (Phesgo®). HTA ID: 20053

2020

• Fluocinolone acetonide intravitreal implant (Iluvien®) for non-infectious uveitis. HTA ID: 20050
• Pembrolizumab (Keytruda®) in combination with axitinib (Inlyta®) for 1L RCC. HTA ID: 19027
• Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion). HTA ID: 20048
• Ozanimod (Zeposia®). HTA ID: 20045
• Sodium hydrogen carbonate (Thamicarb®). HTA ID: 20043
• Delafloxacin (Quofenix®). HTA ID: 20038
• Filgotinib (Jyseleca®). HTA ID: 20047
• Nusinersen (Spinraza®). HTA ID: 20044
• Imipenem/cilastatin/relebactam (Recarbrio®). HTA ID: 20040
• Infliximab (Remsima® subcutaneous). HTA ID: 20042
• Glasdegib (Daurismo®) in combination with low-dose cytarabine. HTA ID: 20041
• Tafamidis (Vyndaqel®). HTA ID: 20017
• Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide for 1L ES-SCLC HTA ID: 19030
• Atezolizumab (Tecentriq®) HTA ID: 20039
• Voretigene neparvovec (Luxturna®) HTA ID: 19041
• Talazoparib (Talzenna®) HTA ID: 19032
• Fremanezumab (Ajovy®)
• Atezolizumab (Tecentriq®) for triple-negative breast cancer.
• Abemaciclib (Verzenios®) HTA ID: 20033
• Ravulizumab (Ultomiris®) HTA ID: 20036
• Dabrafenib plus Trametinib (Tafinlar® plus Mekinist®)
• Vedolizumab (Entyvio®) HTA ID: 20029
• Vedolizumab (Entyvio®) HTA ID: 20030
• Brigatinib (Alunbrig®) HTA ID: 20031
• Apalutamide (Erleada®) for nmCRPC
• Ibrutinib (Imbruvica®) HTA ID:20032
• IUB™ Ballerine® MIDI 15mm diameter SCU300B. HTA ID: 20027
• Lanadelumab (Takhzyro®)
• Indacterol/mometasone furoate (Atectura®) HTA ID: 20024
• Indacterol/glycopyrronium/mometasone furoate (Enerzair®). HTA ID: 20023
• Letermovir (Prevymis®)
• Pembrolizumab (Keytruda®) for Adjuvant melanoma
• Hydroxycarbamide solution (Xromi®). HTA ID: 20020
• Naloxone (Nyxoid®) intranasal spray. HTA ID: 20019
• Durvalumab (Imfinzi®)
• House Dust Mite Extract (Acarizax ®) for Allergic Asthma. HTA ID: 20016
• House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis. HTA ID: 20015
• Benralizumab (Fasenra®) Autoinjector. HTA ID: 20018.
• Andexanet alfa (Ondexxya®). HTA ID: 20014
• Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®)
• Estradiol (Oestrogel® Pump Gel). HTA ID: 20013
• Brolucizumab (Beovu®). HTA ID: 20009
• Meropenem/vaborbactam (Vaborem®). HTA ID: 20007
• Avatrombopag (Doptelet®). HTA ID: 20006
• Olaparib (Lynparza®) (1L maintenance of BRCA-mutated advanced OVCA)
• Infliximab (Remsima SC®). HTA ID: 20012
• Pegaspargase (Oncaspar®) powder for solution for injection/infusion. HTA ID: 20003
• Burosumab (Crysvita®)
• Alutard SQ® honey bee and Alutard SQ® wasp venoms. HTA ID: 19038
• Ravulizumab (Ultomiris®) HTA ID: 19054
• Patisiran (Onpattro®)
• Axicabtagene Ciloleucel (Yescarta®)
• Pegvaliase (Palynziq®) HTA ID: 20001
• Pegvaliase (Palynziq®) HTA ID: 21057
• Lutetium (177Lu) Oxodotreotide (Lutathera®)
• Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer
• Dupilumab (Dupixent®) for moderate-to-severe atopic dermatitis in adolescent patients. HTA ID: 19056
• Co-enzyme Q10 (CoQun®) HTA ID: 19045
• Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)
• Fluoride toothpaste (Duraphat® 5,000 ppm)

2019

• Methyl aminolevulinate (Metvix®) HTA ID: 19049
• Ustekinumab (Stelara®) for Ulcerative colitis HTA ID: 19048
• Dupilumab (Dupixent®)
• Upadacitinib (Rinvoq®) HTA ID: 19047
• Midostaurin (Rydapt®) for AML
• Progesterone (micronised) (Utrogestan®)
• Certolizumab pegol (Cimzia ®) for moderate to severe plaque psoriasis
• Venetoclax (Venclyxto®) in combination with rituximab
• Mepolizumab (Nucala®) 100mg solution in pre-filled pen and syringe
• Levonorgestrel Intrauterine System (Levosert®)
• Zanamivir (Dectova®)
• Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma
• Argipressin acetate (Embesin®)
• Trientine Tetrahydrochloride (TETA 4HCL) – Cuprior®
• Erenumab (Aimovig®)
• Darvadstrocel (Alofisel®)
• Blinatumomab (Blincyto®) CD19+ BCP-ALL
• Tisagenlecleucel (Kymriah®) for DLBCL
• Tisagenlecleucel (Kymriah®) for pALL
• Dolutegravir/Lamivudine (Dovato®)
• Doxylamine/Pyridoxine (Xonvea®)
• Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy
• Niraparib (Zejula®); Recurrent OVCA maintenance treatment
• Olaparib (Lynparza®) tablets for BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer
• Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC
• Romiplostim (Nplate®)
• Ribociclib (Kisqali®) – Updated License
• Gemtuzumab ozogamicin (Mylotarg®)
• Lorlatinib (Lorviqua®)
• Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events
• Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)
• Atezolizumab (Tecentriq® ) for Urothelial Carcinoma 2L
• Vestronidase alfa (MEPSEVII®)
• Magnesium Aspartate Dihydrate (Magnaspartate®)
• Dacomitinib (Vizimpro®)
• Stiripentol (Diacomit®)
• Mannitol Dry Powder (Bronchitol®)
• Olaparib (Lynparza®) for breast cancer
• Opium Tincture (Dropizol®
• Pembrolizumab (Keytruda ®) 1L squamous NSCLC with chemotherapy
• Cerliponase alfa (Brineura®)
• Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L
• Carfilzomib (Kyprolis®) in combination with dexamethasone (CAR+DEX).
• Daratumumab (Darzalex®) in combination with bortezomib and dexamethasone
• Liraglutide (Victoza®)
• Patiromer (Veltassa®)
• Enzalutamide (Xtandi®) for nmCRPC. HTA ID: 18056
• Pertuzumab (Perjeta®) for Adjuvant HER2 positive breast cancer
• Blinatumomab (Blincyto®) (paediatric ALL)
• Budesonide orodispersible tablet (Jorveza®)
• Pentosan Polysulfate Sodium [PPS] (Elmiron®)
• Tivozanib (Fotivda®)
• Encorafenib (Braftovi®), binimetinib (Mektovi®)
• Diclofenac (Itami®)
• Doravirine (Pifeltro®)
• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo®)
• Alectinib (Alecensa®)

2018

• Cariprazine (Reagila®)
• Ozenoxacin (Dubine®)
• Ropivacaine Readyfusor®
• Brigatinib (Alunbrig®)
• Lesinurad (Zurampic®)
• Ixekizumab (Taltz®) for psoriatic arthritis
• Abiraterone acetate (Zytiga®) for mHSPC
• Dinutuximab beta (Qarziba®)
• Avelumab (Bavencio®)
• Ocrelizumab (Ocrevus®) for PPMS
• Atezolizumab (Tecentriq®)
• Tofacitinib (Xeljanz®) for Ulcerative Colitis
• Inotuzumab ozogamicin (Besponsa®)
• Nivolumab (Opdivo®) for urothelial carcinoma
• Tolvaptan (Jinarc®)
• Midostaurin (Rydapt®) for ASM
• Idebenone (Raxone®)
• Ocrelizumab (Ocrevus®) for RMS
• Lenvatinib (Lenvima®) for HCC
• Ribociclib (Kisqali®)
• Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 1L
• Urea (GlucoRx Allpresan®)
• Cladribine (Mavenclad®)
• Dolutegravir/Rilpivirine (Juluca®)
• Cabozantinib (Cabometyx®)
• Venetoclax (Venclyxto®)
• Glycerol Phenylbutyrate (Ravicti®)
• Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)
• Sebelipase alfa (Kanuma®)
• Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)
• Pembrolizumab (Keytruda®) for NSCLC (second line)
• Selexipag (Uptravi®)
• Ertugliflozin (Steglatro®)
• Recombinant Human Parathyroid Hormone (Natpar®)
• Evolocumab (Repatha®)
• Tafamidis meglumine (Vyndaqel®)
• Naltrexone / bupropion (Mysimba®)
• Osimertinib (Tagrisso®)
• Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma
• Eliglustat (Cerdelga®)
• Blinatumomab (Blincyto®)
• Semaglutide (Ozempic®)
• Teduglutide (Revestive®)
• Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)
• Benralizumab (Fasenra®)
• Dimethyl fumarate (Skilarence®)
• Guselkumab (Tremfya®)
• Modified Release Hydrocortisone (Plenadren®)

2017

• Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma
• Emtricitabine/tenofovir disoproxil (TEVA®)
• Nusinersin (Spinraza®)
• Ixazomib (Ninlaro®)
• Tramadol hydrochloride/dexketoprofen (Skudexa®)
• Hyaluronic acid and co enzyme Q10 (VisuXL®)
• Daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone
• Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism
• Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI
• Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)
• Cysteamine bitartrate delayed-release (Procysbi®)
• Lacosamide (Vimpat ®)
• Obeticholic acid (Ocaliva®)
• Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)
• Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic
• Pembrolizumab (Keytruda®) for NSCLC (first line)
• Sarilumab (Kevzara®)
• Sapropterin (Kuvan®)
• Etelcalcetide (Parsabiv®)
• Glecaprevir/Pibrentasvir (Maviret®)
• Brodalumab (Kyntheum®)
• Follitropin delta (Rekovelle®)
• Palbociclib (Ibrance®)
• Emtricitabine / tenofovir disoproxil fumarate (Truvada®)
• Baricitinib (Olumiant®)
• Pitolisant hydrochloride (Wakix®)
• Insulin aspart (Fiasp®)
• Bezlotoxumab (Zinplava®)
• Ceftazidime-avibactam (CEF-AVI)(Zavicefta®)
• Rolapitant (Varuby®)
• Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)
• Alirocumab (Praluent®)
• Migalastat (Galafold®)
• Lenvatinib (Kisplyx®)
• Nivolumab (Opdivo®) for head and neck cancer
• Dalbavancin (Xydalba®)
• Tofacitinib (Xeljanz®)
• Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)
• Crizotinib (Xalkori®) for ROS1 NSCLC
• Crizotinib (Xalkori®) for first line ALK+ NSCLC
• Glycopyrronium bromide (Sialanar®)
• Nivolumab (Opdivo®) for advanced renal cell carcinoma
• Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)
• Trametinib (Mekinist®)
• Daratumumab (Darzalex®)
• Mepolizumab (Nucala®) 100mg powder for solution for injection
• Reslizumab (Cinqaero®)
• Amsacrine (Amsidine®)
• Epoprostenol (Veletri®)
• Obinutuzumab (Gazyvaro®) for Follicular Lymphoma
• Nivolumab (Opdivo®) for classical Hodgkin Lymphoma
• Ustekinumab (Stelara®) for Crohn’s Disease
• Cobimetinib (Cotellic®)
• Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.

2016

• Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)
• Human alpha1-proteinase inhibitor (Respreeza®)
• Elosulfase alfa (Vimizim®)
• Daclizumab (Zinbryta®)
• Vortioxetine (Brintellix®)
• Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)
• Carfilzomib (Kyprolis®) in combination with lenalidomide and dexamethasone (CAR+LEN+DEX)
• Insulin degludec/liraglutide (IDegLira) (Xultophy®)
• Elbasvir/Grazoprevir (Zepatier®)
• Ivacaftor (Kalydeco®) for patients with CF 2 years +
• Nivolumab (Opdivo®) for non-squamous NSCLC
• Ferric maltol (Feraccru®)
• Aceclofenac (Vitafen®)
• Ibrutinib (Imbruvica®) for previously untreated CLL
• Sofosbuvir/Velpatasvir (Epclusa®)
• Loxapine inhalation powder (Adasuve®)
• Ixekizumab (Taltz®)
• Ramucirumab (Cyramza®)
• Trifluridine/tipiracil (Lonsurf®)
• Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)
• Sacubitril/valsartan (Entresto®)
• Safinamide methansulfonate (Xadago®)
• Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)
• Lumacaftor/ivacaftor (Orkambi®)
• Ulipristal acetate (Esmya ®) intermittent treatment
• Etanercept (Benepali®)
• Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer
• Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.
• Isavuconazole (Cresemba®) for the treatment of mucormycosis
• Ticagrelor (Brilique®)
• Apremilast (Otezla®) for psoriatic arthritis.
• Ataluren (Translarna®)
• Emtricitabine/tenofovir alafenamide (Descovy®)
• Ceftolozane/tazobactam (Zerbaxa®)
• Nintedanib (Vargatef®)
• Brivaracetam (Briviact®)
• Sufentanil (Zalviso®)
• Nivolumab (Opdivo®) for Melanoma
• Talimogene Laherparepvec (Imlygic®)
• Nivolumab (Opdivo®) for NSCLC
• Levofloxacin (Quinsair®)
• Fluocinolone acetonide intravitreal implant (Iluvien®) for diabetic macular oedema
• Eltrombopag (Revolade®) for Severe Aplastic Anaemia (SAA)
• Nintedanib (Ofev®)
• Idelalisib (Zydelig®)
• Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)
• Panobinostat (Farydak®)
• Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.
• Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.
• Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.
• Ciclosporin 1mg/ml eye drops (Ikervis®)
• Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)
• Ponatinib (Iclusig®)

2015

• Methoxyflurane (Penthrox®)
• Guanfacine hydrochloride (Intuniv®)
• Idarucizumab (Praxbind®)
• Olaparib (Lynparza®) capsules for BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer
• Secukinumab (Cosentyx®) for Psoriatic Arthritis
• Secukinumab (Cosentyx®) for Ankylosing Spondylitis
• Lenalidomide (Revlimid®)
• Iron (III) isomaltoside 1000 (Monover®)
• Iron (III) isomaltoside 1000 (Diafer®)
• Ledipasvir/sofosbuvir (Harvoni®)
• Vedolizumab (Entyvio®) in Ulcerative Colitis
• Vedolizumab (Entyvio®) in Crohn’s Disease
• Netupitant/palonosetron (Akynzeo®)
• Insulin Glargine (Abasaglar®)
• Ibrutinib (Imbruvica®) for MCL
• Ibrutinib (Imbruvica®) for CLL
• Lidocaine 5% plasters (Versatis®)
• Secukinumab (Cosentyx®) for moderate to severe plaque psoriasis
• Tedizolid phosphate (Sivextro®)
• Ceritinib (Zykadia®)
• Camellia sinensis, folium (green tea leaf) (Catephen 10%®)
• Lenvatinib (Lenvima®)
• Edoxaban (Lixiana®)
• Insulin Glargine U300 (Toujeo®)
• Omalizumab (Xolair®) for the treatment of severe allergic asthma
• Enzalutamide (Xtandi®) pre chemotherapy
• Daclatasvir (Daklinza®)
• St Johns Wort (Pacifa®)
• Insulin Degludec (Tresiba®)
• Dulaglutide (Trulicity®)
• Naloxegel (Moventig®)
• Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia
• Pixantrone (Pixuvri®)
• Simeprevir (Olysio®) in combination with Sofosbuvir
• Pomalidomide (Imnovid®)
• Bedaquiline (Sirturo®)
• Aclidinium bromide / formoterol fumarate dihydrate (Brimica® Genuair®)
• Dimethyl fumarate (Tecfidera®)
• Telavancin (Vibativ®)
• Darunavir & cobicistat (Rezolsta®)

2014

• Pegylated Interferon beta-1a (Plegridy ®)
• Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)
• Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder
• Radium-223 (Xofigo®)
• Sofosbuvir (Solvaldi®)
• Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)
• Regorafenib (Stivarga®) for GIST
• Rituximab (MabThera®)
• Lomitapide (Lojuxta®)
• Nab-paclitaxel (Abraxane®)
• Canagliflozin (Invokana®)
• Insulin aspart (NovoRapid® FlexTouch ®)
• Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
• Cabozantinib (Cometriq®)
• Aripiprazole (Abilify Maintena®)
• Lixisenatide (Lyxumia®)
• Tocilizumab SC (RoActemra®)
• Defibrotide (Defitelio®)
• Simeprevir (Olysio®)
• Umeclidinium/vilanterol (Anoro®)
• Bosentan (Tracleer®)
• Ambrisentan (Volibris®)
• Alemtuzumab (Lemtrada®)
• Trastuzumab emtansine (Kadcyla®)
• Dabrafenib (Tafinlar®)
• Regorafenib (Stivarga®) for mCRC
• Buprenorphine/naloxone (Suboxone®)
• Teriflunomide (Aubagio®)
• Omalizumab (Xolair®)
• Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE
• Empagliflozin (Jardiance®)
• Tadalafil (Adcirca®)
• Sildenafil (Revatio®)
• Riociguat (Adempas®)
• Brimonidine 3.3 mg/g gel (Mirvaso®)
• Clindamycin 1% with tretinoin 0.025% (Treclinac®)
• Oladaterol (Striverdi®, Respimat®)
• Avanafil (Spedra®)
• Brentuximab vedotin (Adcetris®)
• Enzalutamide (Xtandi®) on or after chemotherapy
• Nalmefene (Selincro®)
• Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)
• Dolutegravir (Tivicay®)
• Abiraterone acetate (Zytiga®) for mCRPC post ADT
• Incobotulinum Toxin Type A (Xeomin®)
• Meningitis B Vaccine – February 2014
• Eltrombopag (Revolade®) for Thrombocytopenia in HCV
• Aflibercept (Zaltrap®)
• Macitentan (Opsumit®)
• Liquid Paraffin Ointment (VitA-POS Opthalmic®)
• Sodium Hyaluronate (Hyloforte® 0.2%)
• Sodium Hyaluronate (Hylotear® 0.1%)
• Vismodegib (Erivedge®)

2013

• Dapagliflozin (Forxiga®)
• Fluticasone furoate/vilanterol (Relvar™ Ellipta™)
• Abatacept (Orencia®)
• Alogliptin (Vipidia®)
• Golimumab (Simponi®) for UC
• Pregabalin (Lyrica®) for the treatment of neuropathic pain
• Ulipristal acetate (Esmya®) single course treatment
• Afatinib (Giotrif®)
• Eculizumab (Soliris®)
• Bosutinib (Bosulif®)
• Lipegfilgrastim (Lonquex®)
• Infliximab (Inflectra®)
• Imiquimod 3.75% (Zyclara®)
• Pertuzumab (Perjeta®)
• Crizotinib (Xalkori®)
• Rifaximin (Targaxan®)
• Sodium phenylbutyrate (Pheburane®)
• Icatibant (Firazyr®)
• Perampanel (Fycompa®)
• Ruxolitinib (Jakavi®)
• Ocriplasmin (Jetrea®)
• Linaclotide (Constella®)
• Colistimethate sodium (Colobreathe®)
• Vandetanib (Caprelsa®)
• Apixaban (Eliquis®) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
• Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)
• Omega-3-acid ethyl esters (Omacor®)
• Levonorgestrel intrauterine system LNG-IUS (Jaydess®)
• Pirfenidone (Esbriet®)
• Lisdexamfetamine dimesylate (Tyvense®)
• Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)
• Fidaxomicin (Dificlir®)
• Ivacaftor (Kalydeco®)
• Mirabegron (Betmiga®)

2012

• Aflibercept (Eylea®)
• Decitabine (Dacogen®)
• Bendamustine (Levact®)
• Eribulin (Halaven®)
• Ingenol mebutate gel (Picato®)
• Axitinib (Inlyta®)
• C1inhibitor (human) (Cinryze®)
• Aclidinium bromide (Eklira Genuair®)
• Everolimus (Afinitor®)
• Ceftaroline (Zinforo®)
• Vemurafenib (Zelboraf®)
• Fampridine (Fampyra®)
• Ferumoxytol (Rienso®)
• Glycopyrronium bromide (Seebri Breezhaler®)
• Capsaicin 8%w/w patch (Qutenza®)
• Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery
• Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation
• Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)
• Abiraterone Acetate (Zytiga®) for mCRPC
• Aspirin 81mg/Esomeprazole 20mg (Axanum®)
• Pasireotide (Signifor®)
• Tegafur/Gimeracil/Oteracil (Teysuno®)
• Dexamethasone Intravitreal Implant (Ozurdex®)
• Cabazitaxel (Jevtana®)
• Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis
• Belatacept (Nulojix®)
• Telaprevir (Incivo®)
• Boceprevir (Victrelis®)
• Azilsartan (Edarbi®)
• Rilpivirine (Edurant®)
• Nomegestrol acetate/estradiol (Zoely®)

2011

• Amifampridine (Firdapse®)
• Denosumab (Xgeva®)
• Lotemax 0.5% eye drops suspension (Loteprednol)
• Regadenoson (Rapiscan®)
• Everolimus (Votubia®)
• Grass pollen allergen extract (Oralair®)
• Ticagrelor (Brilique®)
• Oncotype DX®
• Fingolimod (Gilenya®)
• Asenapine (Sycrest®)
• Catumaxomab (Removab®)
• Dexmedetomidine (Dexdor®)
• Hydroxycarbamide (Siklos®)
• Ipilimumab (Yervoy®)
• Linagliptin (Trajenta®)
• Belimumab (Benlysta®)
• Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation
• Lornoxicam (Xefo®)
• Nepafenac (Nevanac®)
• Velaglucerase Alfa (VPRIV®)
• Collagenase Clostridium Histolyticum (Xiapex®)
• Exenatide (Bydureon®)
• Adalimumab (Humira®)
• Vernakalant (Brinavess®)
• Tapentadol (Palexia®)
• Paliperidone palmitate (Xeplion®)
• Tafluprost (Saflutan®)
• Retigabine (Trobalt®)
• Prucalopride (Resolor®)
• Bilastine (Drynol®)
• Iron isomaltoside 1000 (MonoVer®)
• Bazedoxifene (Conbriza®)

2010

• Pitavastatin (Livazo®)
• Tobramycin (TOBI Podhaler®)
• Gefitinib (Iressa®)
• Eltrombopag (Revolade®) for ITP
• Roflumilast (Daxas®)
• Corifollitropin alfa (Elonva®)
• Nilotinib (Tasigna®) newly diagnosed CML
• Dienogest (Visanne®)
• Certolizumab pegol (Cimzia®)
• Denosumab (Prolia®)
• Mifamurtide (Mepact®)
• Oxycodone/naloxone (Targin®)
• Ofatumumab (Arzerra®) (Refractory CLL)
• Golimumab (Simponi®)
• Colesevelam (Cholestagel®)
• Prasugrel (Efient®)
• Rotavirus Vaccine
• Indacaterol (Onbrez®)
• Dronedarone (Multaq®)

2009

• Agomelatine (Valdoxan®)
• Ustekinumab (Stelara®)
• Adenuric (Febuxostat®)
• Ranolazine (Ranexa®)
• Degarelix (Firmagon®)
• Eslicarbazepine (Zebinix®)
• Glucosamine sulfate (Dona®)
• Colorectal Cancer Screening programme

2008

• Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement
• Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement
• Melatonin (Circadin®)
• Human Papillomavirus Vaccine
• Nilotinib (Tasigna®) CML resistant/intolerant to imatinib
• Lapatinib (Tyverb®)

2007

• Sublingual Immunotherapy (Grazax®)
• Natalizumab (Tysabri®)
• Universal Infant Hepatitis B Vaccination programme
• Pneumococcal conjugate vaccine

2006

• Sunitinib (Sutent®)
• Rimonabant (Acomplia®)
• Inhaled insulin (Exubera®)